Skip to main content

Table 1 Characteristics of 1464 patients with prostate cancer

From: Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

Variables n (%), or median (range, mean ± SD)
PSA <4  
 Number of patients 738 (50.4 %)
 Age (y) 76 (35–99, 75.3 ± 9.0)
 WBC (/mL) 5800 (2000–16,100, 6321.3 ± 2203.3)
 Neutrophil (%) 58.8 (4.5–89.0, 59.5 ± 10.3)
 Lymphocyte (%) 29.0 (1.0–60.5, 28.6 ± 8.9)
 NLR 2.02 (0.09–44.5, 2.57 ± 2.33)
4 ≤ PSA <20  
 Number of patients 519 (35.5 %)
 Age (y) 73 (44–99, 72.8 ± 8.2)
 WBC (/mL) 5900 (1100–22,800, 6286.1 ± 2056.8)
 Neutrophil (%) 60.5 (3.0–90.0, 60.6 ± 10.4)
 Lymphocyte (%) 28.6 (3.0–91.0, 28.6 ± 9.2)
 NLR 2.11 (0.03–28.67, 2.57 ± 1.99)
20 ≤ PSA < 100  
 Number of patients 113 (7.7 %)
 Age (y) 76 (54–104, 76.2 ± 8.9)
 WBC (/mL) 6000 (1400–28,500, 6379.7 ± 3919.7)
 Neutrophil (%) 61.4 (7.0–96.7, 61.6 ± 13.1)
 Lymphocyte (%) 27.7 (2.6–82.5, 26.9 ± 11.9)
 NLR 2.21 (0.08–37.19, 3.64 ± 4.78)
100 ≤ PSA < 500  
 Number of patients 53 (3.6 %)
 Age (y) 77 (59–99, 78.0 ± 8.6)
 WBC (/mL) 6300 (1000–26,400, 6664.2 ± 3501.1)
 Neutrophil (%) 66.0 (25.5–95, 64.1 ± 15.1)
 Lymphocyte (%) 22.5 (2.5–61.0, 23.3 ± 11.9)
 NLR 2.83 (0.42–38.00, 4.60 ± 5.75)
500 ≤ PSA  
 Number of patients 41 (2.8 %)
 Age (y) 79 (60–95, 77.3 ± 9.1)
 WBC (/mL) 6400 (2300–48,800, 7973.2 ± 6909.6)
 Neutrophil (%) 69.0 (29.0–60.0, 67.0 ± 14.8)
 Lymphocyte (%) 20.0 (1.5–58.0, 22.2 ± 13.0)
 NLR 3.33 (0.50–60.00, 6.43 ± 10.49)